IMDEGRADER-X
LIVE

Serial Number

79437668

Owner

ImmunoDesigners Co., Ltd.

Attorney

April L. Besl

Filing Date

Sep 24, 2025

Add to watchlist:

No watchlists yet
View on USPTO

IMDEGRADER-X Trademark

Serial Number: 79437668

IMDEGRADER-X is a trademark filed by ImmunoDesigners Co., Ltd. on September 24, 2025. The trademark is classified under Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

ImmunoDesigners Co., Ltd. (2 trademarks)

#1418-1419West buildings,322, Teheran-ro
Gangnam-gu, Seoul 06211 , KR

Entity Type: 03

Trademark Details

Filing Date

September 24, 2025

Registration Date

Not Registered

Published for Opposition

September 8, 2026

Goods & Services

Research and development services in the field of immunology; research and development of vaccines and medicines; biomedical research services; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; pharmaceutical drug development; consultancy relating to pharmaceutical research and development; pharmaceutical research and development; research on the subject of pharmaceuticals; pharmaceutical drug development services.

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 8, 2026 NPUB
PUBLISHED FOR OPPOSITION
Sep 8, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 2, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 14, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 6, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 6, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 6, 2026 TROA
REFUSAL PROCESSED BY IB
Mar 26, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 12, 2026 RFCS
REFUSAL PROCESSED BY MPU
Mar 12, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 7, 2026 RFCR
NON-FINAL ACTION WRITTEN
Feb 6, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 30, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 29, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 29, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 27, 2025 REPR